Onconova Therapeutics- Warrants (01/08/2021) Profit Margin

Onconova Therapeutics- Warrants (01/08/2021) posts a profit margin of 321546.12% as of March 2026. That compares with -8797.22% in the prior-year period — up 3755.1% year over year. That is above the Healthcare sector average of 13.89%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Onconova Therapeutics- Warrants (01/08/2021)'s profit margin was -8797.22%. The latest reading is 321546.12% — a 3755.1% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 13.89% is typical. Onconova Therapeutics- Warrants (01/08/2021)'s 321546.12% is higher that level. That is roughly 2315663.2% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Onconova Therapeutics- Warrants (01/08/2021)'s profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 321546.12% as of March 2026; use YoY and peer views to separate noise from signal.

Context for ONTXW's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.89%), and (3) consistency with growth and profitability. This page covers the first two; Onconova Therapeutics- Warrants (01/08/2021)'s other metric pages and overview cover the third.